SCHEMBL105188

SCHEMBL105188

CC1(C)OB(c2ccc(C(=O)O)cc2)OC1(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 8/20 0.56
LPL P06858 7/20 0.56
P4HB P07237 1/20 0.55
CA1 P00915 6/20 0.50
CA2 P00918 6/20 0.50
CA9 Q16790 6/20 0.50
F11 P03951 3/20 0.50
F2 P00734 2/20 0.50
PRSS1 P07477 2/20 0.50
PRSS2 P07478 2/20 0.50
PRSS3 P35030 2/20 0.50
CA12 O43570 1/20 0.47
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CA5B Q9Y2D0 1/20 0.47
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29049598 0.95 LIPG (0.66) LIPGLPLP4HBCA1CA2
SCHEMBL23493570 0.90 F11 (0.53) LIPGLPLP4HBCA1CA2
SCHEMBL15483243 0.90 P4HB (0.66) LIPGLPLP4HBCA1CA2
SCHEMBL23493571 0.90 F11 (0.53) LIPGLPLP4HBCA1CA2
SCHEMBL3760918 0.86 LPL (0.53) LIPGLPLP4HBCA1CA2
SCHEMBL16595477 0.85 LIPG (0.53) LIPGLPLP4HBCA1CA2
SCHEMBL25196984 0.85 P4HB (0.47) LIPGLPLP4HBCA1CA2
SCHEMBL476844 0.85 LPL (0.52) LIPGLPLP4HBCA1CA2
SCHEMBL5800648 0.84 P4HB (0.62) LIPGLPLP4HBCA1CA2
SCHEMBL17749163 0.83 LIPG (0.48) LIPGLPLP4HBCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES THE JOHNS HOPKINS UNIVERSTY 2023-07-06 US claimed
EP-4157998-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES The Johns Hopkins University (US) 2023-04-05 EP claimed
EP-3344232-B1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY UNIV MCMASTER (CA) 2022-01-26 EP claimed
CN-109053780-B Preparation method of antitumor drug Acalabrutinib key intermediate 浙江合聚生物医药有限公司 2020-09-29 CN claimed
US-10611908-B2 Micelles for mucoadhesive drug delivery MCMASTER UNIVERSITY (CA) 2020-04-07 US claimed
CN-110393805-A Polymer support of nanometer enzyme modification and preparation method thereof, anti-tumor nano particle UNIV WENZHOU MEDICAL 2019-11-01 CN claimed
CN-110343255-A Polymer support and preparation method thereof, anti-tumor nano particle 温州医科大学 2019-10-18 CN claimed
CN-109979663-A A kind of anti-corrosion flame retardant wire and cable and preparation method thereof 陕西正泰电缆有限公司 2019-07-05 CN claimed
US-20180265694-A1 Micelles for Mucoadhesive Drug Delivery MCMASTER UNIVERSITY (CA) 2018-09-20 US claimed
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS INC (US) 2026-05-07 US disclosed
EP-4735422-A1 SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS Sanofi (FR) 2026-05-06 EP disclosed
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES UNIV YALE (US) 2026-04-30 US disclosed
US-20260116869-A1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS NOVARTIS AG (CH) 2026-04-30 US disclosed
EP-4200015-B1 SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL MYERS SQUIBB CO (US) 2026-04-29 EP disclosed
US-6197967-B1 CYCLIZATION OF 4-CARBOXYPHENYLBORONIC ACID WITH HYDRAZIDE DERIVATIVE; HYDROLYSIS; CATALYTIC ESTERIFICATION CLARIANT GMBH (DE) 2001-03-06 US disclosed
EP-1046640-A2 Process for preparing substituted phenyl boronic acids Clariant GmbH (DE) 2000-10-25 EP disclosed
EP-1001766-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-24 EP disclosed
WO-2000027853-A1 HYDROBORONATION PROCESS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2000-05-18 WO disclosed
WO-2000006085-A2 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2000-02-10 WO disclosed
WO-1999001127-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1999-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF CTNNB1, CTNNA1, CTNND1 LIPG 2077/4885LPL 1357/4885P4HB 3304/4885
US-20260116869-A1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS ALK, ACVR1, ACVR1B LIPG 3993/4885LPL 3876/4885P4HB 4428/4885
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, VHL, ADRM1 LIPG 1464/4885LPL 1736/4885P4HB 2463/4885
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES EPX, EPCAM, ELANE LIPG 25/4885LPL 606/4885P4HB 3526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.